Andere talen Sutro Biopharma, Inc.

Aandelen

STRO

US8693671021

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,42 ^USD	0,00%		-9,28%	-20,28%

03/04	SUTRO BIOPHARMA, INC. : Piper Sandler herhaalt koopadvies voor het aandeel	ZM
03/04	SUTRO BIOPHARMA, INC. : Truist Securities handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sutro Biopharma : Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”	04/04
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	02/04
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	02/04
Winfarm : Atos, Ipsen, Voltalia...les valeurs à suivre aujourd'hui à Paris -	02/04
Ipsen : signature d'un accord exclusif avec Sutro Biopharma	02/04
Ipsen : accord de licence mondiale avec Sutro Biopharma	02/04
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	02/04
Ipsen rachète les droits mondiaux de l'anticancéreux STRO-003 à Sutro Biopharma	02/04
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	26/03
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	25/03
Sutro Biopharma to Participate in Upcoming Investor Conferences	06/02
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC	04/01
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	04/01
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR-targeted ADC, on January 4, 2024	15/12
Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from NASDAQ Biotechnology Index	15/12
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024	14/12
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed, Refractory CBF/GLIS Presented at ASH 2023	12/12
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	11/12
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	11/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sutro Biopharma, Inc.

Aandelen

STRO

US8693671021

Andere talen

Filters